Skip to main content
Shanghai No.1 Pharmacy Co.,Ltd. logo

Shanghai No.1 Pharmacy Co.,Ltd. — Investor Relations & Filings

Ticker · 600833 ISIN · CNE000000412 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,256 across all filing types
Latest filing 2026-04-08 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600833

About Shanghai No.1 Pharmacy Co.,Ltd.

https://shdyyy.com.cn/

Shanghai No.1 Pharmacy Co.,Ltd. is a prominent retail and wholesale pharmaceutical enterprise. The company specializes in the distribution of a wide range of healthcare products, including prescription and over-the-counter medicines, traditional Chinese medicine, medical devices, and health supplements. It operates an extensive network of retail pharmacies, providing professional pharmaceutical services and health consultations. As a key subsidiary of the Bailian Group, the company leverages a robust supply chain and a long-standing brand reputation to serve the healthcare needs of its target market. Its operations encompass both physical storefronts and integrated digital platforms, focusing on quality assurance and professional healthcare delivery.

Recent filings

Filing Released Lang Actions
上海第一医药股份有限公司独立董事2025年度述职报告（唐松莲）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2025 Annual Work Report" for Shanghai First Pharmaceutical Co., Ltd. It details the independent director's duties, attendance at board and committee meetings, communication with auditors, oversight of related party transactions, internal controls, and other governance matters for the year 2025. The content is a detailed report on the independent director's activities and assessments during the year, which aligns with a management or board-related report rather than a full annual report or audit report. It is not a financial statement or earnings release, nor is it a brief announcement or proxy material. The document is comprehensive and substantive, focusing on board/management information and governance oversight. Therefore, the best fitting category is Board/Management Information (MANG).
2026-04-08 Chinese
上海第一医药股份有限公司2025年度计提、转回减值的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shanghai First Pharmaceutical Co., Ltd. regarding the provision and reversal of impairment losses for the fiscal year 2025. It details the accounting policies applied, the amounts of credit impairment losses and asset impairment losses, and the impact on the company's consolidated profit. It also includes information about the audit committee and board resolutions approving these impairment provisions. The document is relatively short (2296 characters) and focuses on specific accounting adjustments rather than presenting a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). Instead, it is a regulatory announcement about impairment provisions and related board approvals. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-08 Chinese
上海第一医药股份有限公司2025年度”提质增效重回报“行动方案执行情况评估报告暨2026年度行动方案
Management Reports Classification · 90% confidence The document is titled as an "Execution Evaluation Report of the 2025 Action Plan and the 2026 Action Plan" by Shanghai First Pharmaceutical Co., Ltd. It discusses the company's operational performance, governance, investor relations, and risk management related to the action plans for 2025 and 2026. The content is a detailed report on the execution of a strategic action plan and future plans, including financial and operational aspects, governance improvements, and investor return policies. The document length is 3652 characters, which is relatively short but contains substantive content rather than just an announcement or a link to a report. It is not a typical annual report (10-K) or interim report (IR) but rather a specialized evaluation and planning report. It does not fit into categories like earnings release, call transcript, or regulatory filings. The closest fitting category is "Management Reports (MDA)" because it provides management's detailed explanation of business trends, operational execution, governance, and outlook related to the action plans. Therefore, the document should be classified as MDA with high confidence.
2026-04-08 Chinese
上海第一医药股份有限公司2025年度环境、社会及治理（ESG）报告
Regulatory Filings
2026-04-08 Chinese
上海第一医药股份有限公司审计委员会对2025年度年审会计师履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Audit Committee of Shanghai First Pharmaceutical Co., Ltd. regarding the supervision of the external auditor's performance for the fiscal year 2025. It details the auditor's qualifications, the appointment process, meetings held to discuss audit plans and progress, and an overall evaluation of the auditor's work. The content focuses on the audit committee's oversight and the auditor's fulfillment of their duties, rather than presenting the full annual financial statements or the complete annual report. The document length is 2286 characters, which is relatively short and focused on audit supervision rather than the full annual report. This matches the description of an Audit Report / Information (AR) filing, which includes standalone audit reports and related supervisory information, excluding the full Annual Report (10-K). Therefore, the appropriate classification is AR with high confidence.
2026-04-08 Chinese
上海第一医药股份有限公司2025年度年审会计师履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the audit accounting firm for the fiscal year 2025. It details the qualifications, independence, quality control, audit work plan, resource allocation, information security, and investor protection related to the audit firm engaged by the company. The document does not contain actual financial statements or detailed financial data but rather assesses the audit firm's compliance and performance in conducting the audit. It is not the audit report itself, nor is it an annual report or interim report. The document is a standalone audit-related report focusing on the audit firm's performance and compliance, which fits the category of Audit Report / Information (AR). The document length is 2686 characters, which is short but contains substantive content about audit quality and procedures, not just an announcement or certification. Therefore, the best classification is AR with high confidence.
2026-04-08 Chinese

Browse filings by year

30 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.